Overview: ROMA Score TestIntroduction: The ROMA Score Test calculates ROMA score to assess ovarian cancer risk, helping diagnose causes of pelvic pain or abnormal masses. Affecting 1 in 70 women, ovarian cancer poses diagnostic challenges due to late detection. Following 2023 American College of Obstetricians and Gynecologists (ACOG) guidelines, it uses calculation (HE4, CA-125) for high accuracy, supporting biochemistry screening. This test is vital for diagnosis, treatment planning, and improving outcomes in gynecology.
Other Names: ROMA Risk Score Test, Ovarian Cancer Risk Assay.
FDA Status: FDA-approved test, meeting biochemistry standards for diagnostic reliability.
Historical Milestone: ROMA score testing began in the 2000s with research by Moore, who developed the algorithm. Assay advancements by Abbott improved detection, surpassing earlier CA-125 alone methods.
Purpose: Calculates ROMA score to assess ovarian cancer risk, guides surgery or monitoring, and evaluates patients with pelvic pain, aiming to manage disease.
Test Parameters: ROMA score
Pretest Condition: No special preparation required. Collect serum or plasma. Report history of gynecological issues.
Specimen: Serum (SST, 2-5 mL), Plasma (NaHep, 2-4 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document pelvic pain or abnormal masses. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., metastasis), and sample collection risks.
Procedural Considerations: Uses calculation (HE4, CA-125) to derive score, requiring labs with analyzers. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or contamination can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: High score suggests ovarian cancer risk, guiding therapy. Early detection might improve survival, while untreated cases lead to death. Normal score may require monitoring.
Specialist Consultation: Consult a gynecologist or oncologist for interpretation.
Additional Supporting Tests: Transvaginal ultrasound, CA-125 alone, or biopsy to confirm diagnosis.
Test Limitations: Non-specific for cancer type; correlation with imaging needed. False positives possible with benign conditions.
References: ACOG Guidelines, 2023; Obstetrics & Gynecology, Moore RG, 2022.
